SELLAS Life Sciences Group, Inc.
SLS
$6.44
$1.2223.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.77% | -2.88% | -13.56% | 13.72% | 5.22% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.54% | 0.00% | -0.31% | 25.14% | 0.58% |
| Change in Net Operating Assets | 330.42% | 32.78% | 64.72% | -317.18% | 22.94% |
| Cash from Operations | 30.38% | 3.57% | 19.18% | -26.80% | 8.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -3.89% | -3.92% | -82.06% | 32,651.39% | -99.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 31.72% | -- | -- | -- | -- |
| Cash from Financing | 24.16% | 516.81% | -82.06% | 294,662.50% | -99.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.42% | 713.65% | -121.36% | 303.09% | -160.12% |